Globus Medical Inc   (GMED)
Other Ticker:  
Price: $46.0100 $1.09 2.427%
Day's High: $46.01 Week Perf: -0.13 %
Day's Low: $ 44.41 30 Day Perf: 0.04 %
Volume (M): 1,132 52 Wk High: $ 80.04
Volume (M$): $ 52,065 52 Wk Avg: $58.14
Open: $44.74 52 Wk Low: $43.39

 Market Capitalization (Millions $) 4,683
 Shares Outstanding (Millions) 102
 Employees 3,700
 Revenues (TTM) (Millions $) 1,097
 Net Income (TTM) (Millions $) 204
 Cash Flow (TTM) (Millions $) 156
 Capital Exp. (TTM) (Millions $) 64

Globus Medical Inc
Globus Medical Inc. is a medical device company that develops, manufactures, and markets musculoskeletal implants and surgical products. The company's products are designed for patients suffering from conditions such as spinal disorders, trauma, and joint instability. Globus Medical's product portfolio includes devices for spinal fusion, motion preservation, vertebral compression fracture treatment, and orthopedic trauma.

The company was founded in 2003 by David Paul, a former lawyer who had also worked in the medical device industry. He partnered with his brother, a surgeon, and together they set out to create a company that would revolutionize the field of musculoskeletal care. Since then, the company has grown rapidly, becoming one of the most successful medical device companies in the world.

Globus Medical operates in over 25 countries worldwide, with a strong presence in the United States, Europe, and Asia. The company's headquarters is located in Audubon, Pennsylvania, where it employs approximately 2,500 people. The company also has several manufacturing facilities located in the United States and Europe.

Globus Medical's product portfolio includes more than 160 products across four categories: spine, trauma, Orthobiologics, and joint replacement. The company's spine products comprise of implants and devices that treat conditions such as spinal stenosis, herniated discs, and scoliosis. The company's trauma products include systems that provide treatment for fractures and other injuries. The company's Orthobiologics segment covers various solutions for bone and soft tissue healing. The joint replacement segment provides implants for various joints, including the hip, knee, shoulder, and elbow.

Globus Medical's dedication to research and development has been one of the driving forces behind its success. The company invests heavily in developing innovative products and technologies that improve patient outcomes and reduce healthcare costs. The company has a team of more than 300 engineers and researchers who work to create new products and improve existing ones. Moreover, the company has over 470 patents to its name, reflecting the organization's focus on innovation.

Since going public in 2012, Globus Medical has experienced tremendous growth. The company's revenue has increased from $419 million in 2012 to a whooping $857 million in 2019. The company's commitment to delivering high-quality products and services has earned it numerous industry accolades, including being named one of the fastest-growing companies in the United States in recent times.

In conclusion, Globus Medical Inc is a leading medical device company that has revolutionized the field of musculoskeletal care. The company's strong focus on research and development, combined with its commitment to improving patient outcomes have made it one of the most successful and recognized players in the medical device industry. With its portfolio of innovative products, extensive global reach, and dedicated workforce, the company is poised to continue its growth and dominance in the coming years.

   Company Address: 2560 General Armistead Avenue Audubon 19403 PA
   Company Phone Number: 930-1800   Stock Exchange / Ticker: NYSE GMED
   GMED is expected to report next financial results on February 20, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aurora Technology Acquisition Corp

Aurora Technology Acquisition Corp Faces Declining Operating Behavior, Raising Concerns in Q3 2023

An Overview of Aurora Technology Acquisition Corp's Third Quarter Earnings
As the July to September 30, 2023 earnings season progresses, various companies across different industries are reporting their financial results. One such industry is the Medical Equipment and Supplies sector, which has seen many corporations release their earnings reports. Among them is Aurora Technology Acquisition Corp (ATAK), which recently announced an operating deficit of -$0.4793 million for the third quarter of 2023.
Comparing this figure to the same period in 2022, we can observe a deteriorating operating deficit. In the third quarter of 2022, ATAK reported an operating deficit of -$0.21933 million. This decline raises questions among market participants about the company's ability to generate revenue.

Vivos Therapeutics Inc

Vivos Therapeutics Inc. Defies Financial Odds in the Demanding Times of September 2023

For the fiscal time-frame closing September 30 2023 Vivos Therapeutics Inc decreased a loss per share of $-1.75 per share compare to $-6.50 a year before and Income per Share improved from $-4.50 per share from the preceding reporting season. The revenue crumbled by -31.748 % to $2.90 million from $4.25 million in the corresponding reporting season a year before and sequentially Revenue decreased by -6.456 % from $3.10 million.

Vystar Corporation

Devastating Blow: Medical Equipment and Supplies Company Suffers Major Setback in Q3 2023 Financial Report

Over the past five days, Vystar Corporation has experienced a significant drop in its stock price, declining by -37.78%. Furthermore, the stock is currently trading -20.9% below its 52-week average. In order to better understand the reasons behind this decline, it is essential to examine Vystar Corporation's financial performance for the recent reporting season, which ended on September 30, 2023.
Earnings Per Share and Revenue:
Vystar Corporation reported a considerable improvement in its financial health compared to the previous year. The loss per share decreased from $-0.23 to $-0.03, while the income per share improved from $-0.04. In terms of revenue, there was a significant decline of -98.311% from $3.57 million to $0.06 million compared to the same reporting season a year prior. However, sequentially, the revenue saw an increase of 67.054% from $0.04 million.

Petvivo Holdings Inc

Petvivo Holdings Inc Experiences Widening Losses in Q2 2024 Amid Decrease in Orders

As an investor closely following Petvivo Holdings Inc, the recent financial results have presented a mixed bag of challenges and opportunities. In the second quarter of 2024, the company experienced lower turnover, resulting in a significant revenue decrease and a larger shortfall per share compared to the previous year. However, there were notable signs of potential growth and increasing demand within the Medical Equipment and Supplies industry.
One of the key financial indicators is the revenue, which decreased by -7.127% to $0.21 million year on year. This decline is concerning for Petvivo Holdings Inc, as it points to potential shortcomings in the company's ability to generate sales. Comparatively, the Medical Equipment and Supplies industry as a whole recorded a top-line rise in the same period, suggesting that Petvivo may be facing certain internal challenges.

Ir Med Inc

Ir Med Inc announced operating profit of $1.197 million, in the third quarter of 2023 financial report

As an observer of the Medical Equipment and Supplies sector, I have thoroughly analyzed the third quarter financial results of Ir Med Inc. The company's performance took center stage in this report, overshadowing the same period in the previous year. Despite operating predominantly in the development phase, Ir Med Inc showcased a bullish quarter, signaling potential growth prospects.
Notably, Ir Med Inc reported an operating profit of $1.197 million for the July to September 30, 2023 quarter, without any reported revenue. This indicates that the company is focusing on developing its services rather than generating immediate revenue. Such a strategic course of action is crucial for a business aiming to establish a strong foundation before entering the market.


Globus Medical Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com